STOCK TITAN

Twist Bioscience insider sale: 31,348 shares valued at $1.01M

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice shows an insider proposes to sell 31,348 shares of common stock, with an aggregate market value of $1,008,998.08, representing approximately 0.052% of the 60,360,925 shares outstanding. The shares were acquired through restricted stock vesting on 10/01/2025 and the approximate sale date is 10/06/2025. The filing lists prior insider sales in the past three months totaling 12,746 shares for gross proceeds of $348,121.10, with individual sale dates between 08/04/2025 and 10/02/2025. The filer attests there is no undisclosed material adverse information and notes the securities were received as compensation.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans to sell a modest stake after restricted shares vested; recent sales have been small relative to outstanding stock.

The filing discloses a proposed sale of 31,348 shares valued at $1,008,998.08 with an approximate sale date of 10/06/2025. These shares were acquired via restricted stock vesting on 10/01/2025, and prior dispositions in the last three months totaled 12,746 shares for $348,121.10. As an insider sale notice under Rule 144, it documents a compliant, scheduled disposition following vesting and does not itself disclose operational changes.

The transaction size is small relative to total shares outstanding (0.052%), which reduces direct dilution or control concerns. Key things to watch in the near term are whether additional Form 4 or Form 144 filings appear and whether the insider shifts to larger, unscheduled sales over the next 90 days.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TWST Form 144 disclose?

It discloses a proposed sale of 31,348 common shares valued at $1,008,998.08, acquired by restricted stock vesting on 10/01/2025, with an approximate sale date of 10/06/2025.

Who is the seller named in the filing for TWST?

The filing lists sales by Emily M. Leproust and the current notice references a person for whose account the 31,348 shares are to be sold.

How many shares were sold by the insider in the prior three months?

Insider sales in the prior three months totaled 12,746 shares, generating gross proceeds of $348,121.10.

What was the acquisition method for the 31,348 shares?

The shares were acquired through restricted stock vesting on 10/01/2025 and payment was recorded as compensation.

How material is the proposed sale relative to TWST outstanding shares?

The proposed sale represents approximately 0.052% of the 60,360,925 shares outstanding, a relatively small proportion.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.77B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO